
Key takeaways
- An Item 3.01 filing must be submitted within four business days of receiving a deficiency notice from an exchange.
- The most common trigger is a minimum bid price falling below $1.00 for 30 consecutive business days.
- New 2024 rules eliminate standard cure periods for companies that have performed a reverse stock split in the prior year.
Understanding the Regulatory Framework of an Item 3.01 Delisting Notice
The Item 3.01 delisting notice serves as a critical transparency mechanism within the U.S. financial system, governed by the Securities Exchange Act of 1934. Specifically, Section 12(b) and 12(d) of the Act provide the statutory authority for national securities exchanges to set standards for the companies that trade on their platforms. When a company falls short of these standards—whether they pertain to financial health, stock price, or corporate governance—it must file a Form 8-K under Item 3.01. This requirement, formally titled 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,' ensures that the public is aware of any threat to the security's listing status. Under Exchange Act Rule 12d2-2, the formal removal of a class of securities is a multi-step process that begins with this disclosure. Investors should view this notice not necessarily as an end, but as the start of a regulated procedure intended to protect the integrity of the exchange and provide the company a window to rectify its issues. The filing must be made within four business days of the notification from the exchange, ensuring that material information regarding the stock's eligibility for trading reaches the market promptly. This regulatory framework balances the needs of the exchanges to maintain high standards with the rights of investors to be informed of potential changes in a security's liquidity and trading venue.
Common Triggers Leading to an Item 3.01 Delisting Notice
There are several ways a company can find itself in receipt of an Item 3.01 delisting notice, but the most frequent involve price and liquidity thresholds. For both the Nasdaq and the NYSE, a primary trigger is the 'Minimum Bid Price' rule. If a stock's closing bid price remains below $1.00 for 30 consecutive business days, the exchange will issue a deficiency notice. However, price is not the only metric. Under the Nasdaq Rule 5810 series, companies can also be flagged for falling below the minimum Market Value of Listed Securities (MVLS). As of a July 2024 update, Nasdaq-listed companies are required to maintain a minimum MVLS of $5 million. Falling below this threshold for 30 consecutive business days now triggers a delisting determination that, notably, does not carry an automatic cure period. Other triggers involve corporate governance failures, such as failing to maintain an audit committee comprised of independent directors or neglecting to hold an annual meeting of shareholders. Furthermore, financial reporting delays are a significant precursor. If a company fails to file its Form 10-K or Form 10-Q on time, it will often file a Form 12b-25 (Notice of Late Filing) first, followed shortly by an Item 3.01 notice as the exchange reacts to the lapse in periodic reporting requirements. These triggers are designed to ensure that only companies meeting baseline transparency and stability standards remain accessible on major public markets.
Want this tracked for you?
ALFA Finder watches every SEC filing 24/7 and alerts you the moment one matters.
Comparison of Nasdaq and NYSE Continued Listing Standards
| Requirement | Nasdaq (Rule 5810 Series) | NYSE (Section 802.01) |
|---|---|---|
| Minimum Bid Price Trigger | Below $1.00 for 30 consecutive business days | Below $1.00 for 30 consecutive trading days |
| Standard Cure Period | 180 calendar days | 6 months |
| Compliance Requirement | At least $1.00 for 10 consecutive business days | At least $1.00 on last day of month and $1.00 avg over 30 days |
| Market Value Requirement | $5 million MVLS (New 2024 threshold) | Varies by listing standard (e.g., $50M over 30 days) |
| Filing Late Reports | Immediate deficiency notice | Immediate deficiency notice; 6-month cure possible |
The Timeline and Path to Regaining Compliance
Receiving an Item 3.01 delisting notice initiates a highly structured 'compliance period' or 'cure period.' For price-based deficiencies, companies are typically granted an automatic 180-day calendar period to regain compliance. During this time, the stock continues to trade normally on the exchange, though it may be marked with a suffix or indicator in certain data feeds to warn traders of the deficiency. To 'cure' a price deficiency, the stock must generally maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. It is important to note that the exchange has the discretion to extend this requirement to 20 consecutive days if the stock price is particularly volatile. If the company fails to meet this requirement within the first 180 days, it may be eligible for a second 180-day period, provided it meets certain other financial requirements and notifies the exchange of its intent to cure the deficiency, often via a reverse stock split. However, the path to compliance is not merely about price; the company must also remain current in its SEC filings. If the deficiency is related to late financial statements, the company must work with the exchange to provide a plan of compliance, which often involves an 'Adjudicatory Body' or hearings panel. For investors, the timeline is vital because it determines how long the stock will remain liquid on a major exchange before potentially being relegated to the Over-The-Counter (OTC) markets.
The Typical Lifecycle of a Delisting Event
- The exchange identifies a breach of continued listing rules (e.g., 30 days below $1.00).
- The exchange sends a formal deficiency notice to the company.
- The company files a Form 8-K with Item 3.01 disclosure within four business days.
- A 180-day cure period begins, during which the company explores options like a reverse stock split.
- If the deficiency is cured (10+ days above $1.00), the exchange sends a compliance letter and the matter is closed.
- If the deficiency is not cured, the exchange issues a 'Staff Delisting Determination' letter.
- The company may appeal to a Hearings Panel, which can stay the delisting temporarily.
- If the appeal fails, the exchange files Form 25-NSE with the SEC to finalize the removal.
The 2024 'Reverse Split Trap' and Accelerated Delisting Rules
Recent regulatory shifts have made the path to regaining compliance much narrower for certain companies. In late 2024 and early 2025, both Nasdaq and the NYSE adopted more stringent rules regarding reverse stock splits, which are frequently used to artificially boost a share price above the $1.00 threshold. Under the new Nasdaq Rule 5810(c)(3)(A)(iv), if a company falls below the $1.00 minimum bid price and has performed a reverse stock split within the prior one-year period, it is no longer eligible for a compliance period. Instead, the company faces an immediate 'Staff Delisting Determination.' This effectively eliminates the 'revolving door' of reverse splits that some distressed companies used to stay listed indefinitely. Additionally, a new rule regarding 'Secondary Deficiencies' means that if a company performs a reverse split to fix its price but consequently falls below another requirement—such as the minimum 500,000 publicly held shares—it will not receive a separate cure period for that new problem. These changes significantly increase the risk for investors holding 'penny stocks' on major exchanges, as the traditional 180-day safety net can now vanish instantly if the company has a history of recent capital restructuring. Understanding these nuances is essential for traders who specialize in turnaround plays or small-cap stocks, as the window for an exit can close much faster than in years past.
Finding and Analyzing Delisting Filings on EDGAR
For a retail investor, monitoring for an Item 3.01 delisting notice requires a proactive approach to the SEC’s EDGAR database. When a company is under pressure, investors should look for 'precursor' documents, most notably the Form 12b-25. This 'Notice of Late Filing' often signals that a company is struggling with its internal controls or financial health, which frequently triggers an exchange deficiency notice shortly thereafter. To find the actual delisting notice, search for the company's ticker on EDGAR and look specifically for a 'Form 8-K' where 'Item 3.01' is cited on the cover page or within the 'Items' list. Investors using tools like ALFA Finder can set alerts for these specific tags to ensure they receive a notification the moment the filing hits the public record, bypassing the need for manual searches. It is also important to distinguish between the various forms used at the end of the process. A 'Form 25' is typically filed by the company when it chooses to delist voluntarily (for example, after a merger). Conversely, a 'Form 25-NSE' is filed by the Exchange itself to finalize an involuntary removal. By the time a Form 25-NSE is filed, the trading venue change is usually imminent or has already occurred. Reading the text of the Item 3.01 filing is also crucial, as it will detail the specific rule violated and the date by which the company must regain compliance, providing a clear deadline for the investor's thesis.
What Happens to Shareholders After Delisting?
A common misconception among retail investors is that an Item 3.01 delisting notice means the stock is becoming worthless or the company is going out of business. In reality, delisting is a change of trading venue, not a liquidation of the company. If a company fails to regain compliance and is removed from the NYSE or Nasdaq, its shares usually migrate to the Over-The-Counter (OTC) markets, specifically the OTCQX, OTCQB, or the 'Pink Sheets.' While your shares still represent the same ownership stake in the company, the transition typically results in a significant loss of liquidity. On the OTC markets, the gap between the 'bid' and 'ask' prices (the spread) often widens, making it more expensive to enter or exit a position. Furthermore, many institutional investors and mutual funds are prohibited by their charters from holding stocks that do not trade on a national exchange, which often leads to forced selling and downward price pressure during the transition. Automated platforms like ALFA Finder allow traders to filter for companies currently in their 180-day cure period, helping them track which stocks are at the highest risk of this venue change. While some companies successfully navigate the OTC markets and eventually 're-list' on a major exchange, the vast majority of delisted stocks struggle to regain their former valuations. As such, the appearance of an Item 3.01 filing should be treated as a high-priority risk signal that requires a re-evaluation of the investment's risk-reward profile.
Frequently asked questions
Does an Item 3.01 filing mean the stock will be delisted tomorrow?
No. In most cases, an Item 3.01 filing signifies the beginning of a deficiency process. For price-related issues, companies are usually given a 180-day cure period to regain compliance before any actual removal occurs.
Can a company appeal a delisting determination?
Yes. If a company receives a Staff Delisting Determination after the cure period expires, it can request a hearing before an independent panel. This request usually stays (pauses) the delisting process until the panel reaches a decision.
What is the difference between a Form 25 and a Form 25-NSE?
A Form 25 is filed by the company, typically for voluntary delisting due to a merger or private buyout. A Form 25-NSE is filed by the exchange (National Securities Exchange) to formally and involuntarily remove a company that failed to meet listing standards.
How long must a stock stay above $1.00 to regain compliance?
Generally, a stock must maintain a closing bid price of at least $1.00 for 10 consecutive business days. However, the exchange has the discretion to require the price to remain above that level for up to 20 consecutive business days if the stock is highly volatile.
Educational and informational content only — not investment advice. ALFA Finder is not a registered investment adviser. Check figures against the original SEC filing before acting on them.


